Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences in CD33 intensity between various myeloid neoplasms.

Iman Jilani1, Elihu Estey, Yang Huh

  • 1Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

American Journal of Clinical Pathology
|October 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.

Inflammatory bowel diseases·2025
Same author

Adultification of Young Black Females on Their Health and Well-being: A Qualitative Study.

Pediatrics·2025
Same author

The Impact of Living at Moderate Altitude in the USA: Epidemiology and Key Research Questions.

Gerontology·2025
Same author

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Leukemia·2025
Same author

Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction.

Translational oncology·2024
Same author

Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.

Leukemia research·2024
Same journal

Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.

American journal of clinical pathology·2026
Same journal

CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

American journal of clinical pathology·2026
Same journal

Comprehensive multicriteria life cycle assessment of biopsy processing in a surgical pathology department.

American journal of clinical pathology·2026
Same journal

Prognostic significance of Myb protein and its downstream target genes in lacrimal gland adenoid cystic carcinoma.

American journal of clinical pathology·2026
Same journal

Mismatch repair protein "nonclassic expression loss" pattern in colorectal cancer: an important staining pattern that is not well understood.

American journal of clinical pathology·2026
Same journal

Musculoskeletal pain in medical laboratory personnel: a cross-sectional study.

American journal of clinical pathology·2026
See all related articles

CD33 antigen expression varies significantly across different leukemia types, with higher levels observed in bone marrow compared to peripheral blood. This finding highlights potential diagnostic and therapeutic implications for CD33 in myeloid malignancies.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • CD33 is a cell surface antigen expressed on myeloid cells.
  • Its expression levels can vary in hematological malignancies.
  • Understanding CD33 expression is crucial for leukemia diagnosis and targeted therapy.

Purpose of the Study:

  • To quantify and compare CD33 antigen concentration in bone marrow and peripheral blood across various leukemia types and controls.
  • To investigate the correlation of CD33 expression with leukemia subtypes, patient age, and clinical outcomes.

Main Methods:

  • Flow cytometry was used to measure CD33 antigen concentration on cells from 315 bone marrow and 114 peripheral blood samples.
  • Samples were from patients with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myeloproliferative disorder (MPD), myelodysplastic syndrome (MDS), and healthy controls.

Related Experiment Videos

  • Statistical analyses were performed to compare CD33 intensity across different groups and clinical parameters.

    • Main Results:

    • Overall CD33 intensity was significantly higher in bone marrow than peripheral blood.
    • CD33 intensity differed significantly among leukemia types, being highest in AML, followed by MDS, CML, and MPD.
    • CD33 expression on CD34+ cells was highest in AML and lowest in MPD.
    • Younger patients (<60 years) with AML or MDS showed higher CD33 expression on CD34+ cells compared to older patients.
    • No correlation was found between CD33 intensity and cytogenetics, therapy response, or overall survival in patients treated with Mylotarg.

    Conclusions:

    • CD33 antigen expression exhibits significant variability across different types of leukemia.
    • Bone marrow CD33 levels are generally higher than peripheral blood levels.
    • Age influences CD33 expression in AML and MDS, with younger patients showing higher intensity.
    • CD33 intensity did not correlate with treatment outcomes in this cohort, suggesting complex roles in disease progression and therapy response.